Kura Oncology, Inc. (KURA)
| Market Cap | 859.22M +65.5% |
| Revenue (ttm) | 67.48M +25.2% |
| Net Income | -278.67M |
| EPS | -3.18 |
| Shares Out | 88.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,834,525 |
| Open | 9.52 |
| Previous Close | 9.51 |
| Day's Range | 9.38 - 9.94 |
| 52-Week Range | 5.45 - 12.49 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 27.38 (+182.85%) |
| Earnings Date | May 12, 2026 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n... [Read more]
Financial Performance
In 2025, Kura Oncology's revenue was $67.48 million, an increase of 25.24% compared to the previous year's $53.88 million. Losses were -$278.67 million, 60.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price target is $27.38, which is an increase of 182.85% from the latest price.
News
Kura Oncology reports Q1 EPS (83c), consensus (78c)
Reports Q1 revenue $18.27M, consensus $25.92M. As of March 31, Kura had $580.8M in cash, cash equivalents and short-term investments, compared to $667.2M as of December 31, 2025. The company…
Kura Oncology Earnings Call Transcript: Q1 2026
KOMZIFTI's launch exceeded expectations with $5.8M in Q1 revenue, strong physician adoption, and 40% combination use. Phase III programs are ahead of plan, and robust cash reserves support continued clinical and commercial expansion.
Kura Oncology Reports First Quarter 2026 Financial Results
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and com...
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
Kura Oncology, (KURA) and Kyowa Kirin (KYKOF) announced that updated results from the frontline arm of the Phase 1 KOMET-007 clinical trial evaluating ziftomenib in combination with cytarabine plus da...
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...
Kura Oncology to Report First Quarter 2026 Financial Results
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – – Regulatory Filing in Japan Planned Following Clinical Trial Completion –
Kura Oncology Transcript: Investor Update
Updated Phase 1 data show darlifarnib plus cabozantinib achieves a 44% objective response rate and 94% disease control in heavily pretreated, cabozantinib-refractory RCC patients, with a favorable safety profile. Expansion into cabozantinib-naive patients and broader solid tumor combinations is underway.
Kura Oncology reports results from ongoing FIT-001 clinical trial
Kura Oncology (KURA) announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib in the ongoing FIT-001 clinical trial o...
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy
Kura Oncology initiated with a Buy at Lake Street
Lake Street initiated coverage of Kura Oncology (KURA) with a Buy rating and $23 price target The firm’s price target is based on the market opportunity for the company’s commercial…
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy
Syndax assumed with a Buy at Jefferies
Jefferies assumed coverage of Syndax (SNDX) with a Buy rating and a price target of $40, down from $48. Revuforj is winning today and the competition from Kura Oncology (KURA)…
Kura Oncology price target lowered to $25 from $30 at Mizuho
Mizuho analyst Salim Syed lowered the firm’s price target on Kura Oncology (KURA) to $25 from $30 and keeps an Outperform rating on the shares. The firm, which moved Komzifti…
Kura Oncology price target lowered to $15 from $16 at UBS
UBS analyst David Dai lowered the firm’s price target on Kura Oncology (KURA) to $15 from $16 and keeps a Buy rating on the shares.
Kura Oncology Transcript: Barclays 28th Annual Global Healthcare Conference
Komzifti's launch is exceeding expectations with strong payer uptake and positive KOL feedback. Ziftomenib's development is advancing with streamlined global trials and upcoming data updates, while tipifarnib combinations target resistance in KRAS and RCC with promising safety and efficacy.
Kura Oncology Transcript: Leerink Global Healthcare Conference 2026
KOMZIFTI's launch has achieved rapid market access and strong initial sales, with ambitions to lead the NPM1 mutant AML market and expand into larger frontline opportunities. Multiple clinical data readouts for ziftomenib and darlifarnib are expected this year, supported by a robust cash position and strategic partnerships.
Kura Oncology price target raised to $30 from $29 at BofA
BofA raised the firm’s price target on Kura Oncology (KURA) to $30 from $29 and keeps a Buy rating on the shares. While the firm thought “there was a lot…
Kura Oncology price target lowered to $36 from $38 at Wedbush
Wedbush lowered the firm’s price target on Kura Oncology (KURA) to $36 from $38 and keeps an Outperform rating on the shares after the company reported fourth quarter financials and…
Kura Oncology reports inducement grants under Nasdaq listing rule
Kura Oncology (KURA) announced that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase 44,7...
Kura Oncology Earnings Call Transcript: Q4 2025
2025 saw a successful Komzifti launch with $2.1M in revenue, rapid payer adoption, and strong clinical feedback. The company is advancing a broad AML and solid tumor pipeline, with robust cash reserves and multiple catalysts expected in 2026.
Kura Oncology reports Q4 EPS (92c), consensus (49c)
Reports Q4 revenue $17.34M, consensus $35.45M. As of December 31, 2025, Kura had $667.2M in cash, cash equivalents and short-term investments, compared to $727.4M as of December 31, 2024.”We are…
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, ...